Novartis Investigative Site

Nagano, Nagano 3808582

0 studies enrolling now · 5 studies all time

What they study most

Atherosclerosis, Polymyalgia Rheumatica, Rheumatoid Arthritis

Studies at this site

• Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) — Running, not enrolling
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents — Completed
• Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. — Stopped early